A synthetic melanocortin receptor agonist. FDA approved as Vyleesi for HSDD in premenopausal women. Acts centrally to promote sexual arousal and desire in both men and women, without the tanning effects of MT-2.
Dosing & Protocols
1-2mg subcutaneous 45 min to 2 hours before activity. Test dose 0.5mg first. Maximum 1 injection per 24 hours. Recommended maximum: once per 72 hours to reduce nausea.
Side Effects
Nausea very common, facial flushing, headache, transient blood pressure increase. Nausea mitigated by lower doses or anti-nausea pretreatment.
Interactions & Contraindications
Contraindicated with high-risk cardiovascular conditions. Avoid with blood pressure medications. Do not combine with PDE5 inhibitors without medical supervision.
Storage
Freeze lyophilized. Refrigerate after reconstitution, use within 30 days.
Disclaimer: All information is for research purposes only. Not medical advice.